Could Anthropic Managed Agents Pressure The Doximity SaaS Business Model

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.

• Anthropic recently introduced Managed Agents, a new service that can run autonomous AI workflows for businesses.

• This model could reduce the need for traditional seat-based software subscriptions that charge per user.

• Doximity (NYSE:DOCS), which relies heavily on a SaaS model for clinicians and life sciences customers, could face a new type of competitive pressure.

Doximity runs a digital platform for U.S. clinicians, combining professional networking, telehealth tools, and workflow software under a subscription model. At the same time, large AI providers are starting to offer plug and play infrastructure such as Anthropic's Managed Agents that lets enterprises automate tasks directly on top of their data and systems. For NYSE:DOCS, that shift raises questions around how much value sits in its software interface versus what could be handled by more generic AI orchestration.

For you as an investor, the key issue is how AI infrastructure like Managed Agents might change customer expectations around pricing, integration, and flexibility. The story here is less about near term numbers and more about whether Doximity can keep its tools essential if clients can increasingly spin up autonomous AI workflows without relying as heavily on seat based SaaS platforms.

Stay updated on the most important news stories for Doximity by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Doximity.

📰 Beyond the headline: 0 risks and 4 things going right for Doximity that every investor should see.

Quick Assessment

• ✅ Price vs Analyst Target: At US$21.05, Doximity trades about 46% below the US$39.05 analyst price target.

• ✅ Simply Wall St Valuation: Shares are flagged as trading 57.8% below the estimated fair value.

• ❌ Recent Momentum: The 30 day return is about a 14.6% decline.

To assess whether it may be the right time to buy, sell or hold Doximity, you can review Simply Wall St's company report for the latest analysis of Doximity's fair value.